



January 2022 Pharmacy & Therapeutics Committee Decisions

UCare’s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to UCare formularies (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for the Medicare formularies are tentative until UCare receives final CMS approval.

Key:

Medicare: UCare Medicare, UCare Medicare with Fairview and North Memorial, UCare Group Medicare, EssentiaCare, Minnesota Senior Health Options (MSHO) & Connect + Medicare

Medicaid: PMAP, MnCare, MSC+ & Connect

Exchange: UCare Individual and Family Plans

F: Formulary

NF: Non-formulary

PA: Prior Authorization

QL: Quantity Limit

ST: Step Therapy

New Drug Review			
Drug	Indication	Formulary Coverage	Effective Date
Tivdak (tisotumab vedotin-tftv) PROTECTED CLASS	treatment of adults with recurrent or metastatic cervical cancer with progression on or after chemotherapy	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary	N/A
Bylvay (odevixibat)	treatment of pruritus in patients ≥ 3 months of age with progressive familial intrahepatic cholestasis (PFIC).	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary	N/A
Livmarli (maralixibat)	treatment of cholestatic pruritus in patients with Alagille syndrome who are ≥ 1 year of age.	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary	N/A
TicoVac (tick-borne encephalitis vaccine)	Active immunization to prevent tick-borne encephalitis in patients ≥ 1 year of age	Medicare: Formulary Medicaid: Formulary Exchange: Formulary	2/1/2021
Exkivity (mobocertinib succinate)	locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults with epidermal growth factor receptor (EGFR) exon 20 insertion mutations	Medicare: Formulary w/PA Medicaid: Formulary w/PA Exchange: Formulary w/PA	2/1/2021



January 2022 Pharmacy & Therapeutics Committee Decisions

Formulary changes for New Generics, New Indications and Miscellaneous Previously Reviewed drugs are effective 2/1/2022.

New Indications Review		
Drug	Current formulary status	Recommendation
Jakafi	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Repatha	Medicare - F, Medicaid - NP, HIX - F	Medicare - F, Medicaid - NP, HIX - F
Biktarvy	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Flucelvax	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Vimpat	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Verzenio	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Dupixent	Medicare - F, Medicaid - NP, HIX - F	Medicare - F, Medicaid - NP, HIX - F
Tasigna	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Erbitux	Medicare - NF, Medicaid - NF, HIX - NF	Medicare - NF, Medicaid - NF, HIX - NF
Tecartus	Medicare - NF, Medicaid - NF, HIX - NF	Medicare - NF, Medicaid - NF, HIX - NF
Keytruda	Medicare - NF, Medicaid - NF, HIX - NF	Medicare - NF, Medicaid - NF, HIX - NF
Tecentriq	Medicare - NF, Medicaid - NF, HIX - NF	Medicare - F, Medicaid - NF, HIX - NF
Ruxience	Medicare - NF, Medicaid - NF, HIX - NF	Medicare - NF, Medicaid - NF, HIX - NF
Mvasi	Medicare - NF, Medicaid - NF, HIX - NF	Medicare - NF, Medicaid - NF, HIX - NF
Cutaquiq (immune globulin)	Medicare - NF, Medicaid - NF, HIX - NF	Medicare - NF, Medicaid - NF, HIX - NF

Miscellaneous Previously Reviewed Items		
Drug	Rationale/Alternative	Recommendation
Thalitone (chlorthalidone)	Expensive strength (15mg) \$110 vs \$4 for 25mg	NF all lines of business
Diclofenac potassium tablet	Expensive strength (25mg) \$1950 vs \$18 for 50mg	NF all lines of business

January 2022 Pharmacy & Therapeutics Committee Decisions

Rosuvastatin-ezetimibe	Cover each entity separately	NF all lines of business
Loreev XR (lorazepam)	Numerous BZDs covered with variable t ¹ / ₂ s \$285 vs \$5 for non ER	NF all lines of business
Invega Hafyera	6 month formulation (cover 3, 4 mo)	Medicare: F, Medicaid: F, HIX: F
Trudhesa (dihydroergotamine) Nasal Spray	Cover dihydroergotamine nasal spray and oral tablets	NF all lines of business
Fenofibrate capsule	Expensive strength (30mg, 90mg) \$450 vs \$20 for 67mg or 134mg	NF all lines of business

Additional Items Reviewed

Item	Action
New Medical Drug Policies	<ul style="list-style-type: none"> Approved adding new policies for Vyvgart, Susvimo and Purified Cortrophin Gel